Prediction of personalized drugs based on genetic variations provided by DNA sequencing technologies
- 238 Downloads
Recent reports of death and illness caused by adverse drug reactions have boosted rational drug design research. It has been shown through sequencing of the entire human genome that human genetic variations play a key role in adverse reactions to drugs as well as in differences in the effectiveness of drug treatments. The advent of high-throughput DNA sequencing technologies with bioinformatics of system biology have allowed the easy identification of genetic variations and all other pharmacogenetic variants in a single assay, thus permitting truly personalized drug treatment. This would be particularly valuable for many patients with chronic diseases who must take many medications concurrently. In this review, we have focused on pharmacogenomics for the prediction of variable drug responses between individuals with relevant genetic variations through new DNA sequencing technologies and provided directions for personalized drug therapy in the future.
KeywordsNew DNA sequencing Genome analysis Single nucleotide polymorphisms (SNPs) Pharmacogenomics Personalized drugs
Unable to display preview. Download preview PDF.
- Buch S, Schafmayer C, Volzke H, Becker C, Franke A, von Eller-Eberstein H, Kluck C, Bassmann I, Brosch M, Lammert F, et al. (2007) A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat. Genet. 39: 995–999.PubMedCrossRefGoogle Scholar
- Clark LN, Kisselev S, Park N, Ross B, Verbitsky M, Rios E, Alcalay RN, Lee JH, and Louis ED (2010) Mutations in the Parkinson’s disease genes, Leucine Rich Repeat Kinase 2 (LRRK2) and Glucocerebrosidase (GBA), are not associated with essential tremor. Parkinsonism Relat. Disord. 16: 132–135.PubMedCrossRefGoogle Scholar
- Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, Rafnar T, Gudbjartsson D, Agnarsson BA, Baker A, et al. (2007) Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat. Genet. 39: 977–983.PubMedCrossRefGoogle Scholar
- Guillem VM, Cervantes F, Martinez J, Alvarez-Larran A, Collado M, Camos M, Sureda A, Maffioli M, Marugan I, and Hernandez-Boluda JC (2010) XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia. Am. J. Hematol. 85: 482–486.PubMedCrossRefGoogle Scholar
- Hay DC, Zhao D, Fletcher J, Hewitt ZA, McLean D, Urruticoechea-Uriguen A, Black JR, Elcombe C, Ross JA, Wolf R, et al. (2008) Efficient differentiation of hepatocytes from human embryonic stem cells exhibiting markers recapitulating liver development in vivo. Stem Cells 26: 894–902.PubMedCrossRefGoogle Scholar
- Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 97: 3473–3478.PubMedCrossRefGoogle Scholar
- Jones M (2009) Francis Collins Addresses State of Personalized Medicine. GenomeWeb [online], http://www.genomeweb.com/dxpgx/francis-collin-addresses-state-personalized-medicine.
- Libioulle C, Louis E, Hansoul S, Sandor C, Farnir F, Franchimont D, Vermeire S, Dewit O, de Vos M, Dixon A, et al. (2007) Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet. 3: e58.PubMedCrossRefGoogle Scholar
- Lowe CE, Cooper JD, Brusko T, Walker NM, Smyth DJ, Bailey R, Bourget K, Plagnol V, Field S, Atkinson M, et al. (2007) Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat. Genet. 39: 1074–1082.PubMedCrossRefGoogle Scholar
- McVean G, Spencer CC, and Chaix R (2005). Perspectives on human genetic variation from the HapMap Project. PLoS Genet. 1; e54.Google Scholar
- Molanaei H, Carrero JJ, Heimburger O, Nordfors L, Lindholm B, Stenvinkel P, Odar-Cederlof I, and Bertilsson L (2010) Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease. Eur. J. Clin. Pharmacol. 66: 269–273.PubMedCrossRefGoogle Scholar
- Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, Green T, Kuballa P, Barmada MM, Datta LW, et al. (2007) Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat. Genet. 39: 596–604.PubMedCrossRefGoogle Scholar